If the blood test - from California-based biotechnology company Freenome - was approved for market, it would be one of the ...

Researchers investigated the factors associated with treatment delay in patients with early-onset colorectal cancers.

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

A new test developed in the UK can accurately predict whether high-risk patients will develop bowel cancer, also known as colorectal cancer, in the five years.

Exelixis, Inc. (NASDAQ:EXEL), a biopharmaceutical company with a market capitalization of $9.4 billion focused on developing and commercializing novel therapies for cancer treatment, stands at a ...

An accurate new blood test for colon cancer, the fourth leading cause of cancer deaths in the US, has been reported.

Dwyane Wade reflected on having a cancerous tumor removed from his kidney as well as 40 percent of the organ itself after ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

More than 67,000 Americans will be diagnosed with pancreatic cancer this year. Learn more about the disease and how PanCAN can help.